Literature DB >> 30527105

Maternal and perinatal outcomes associated with the use of renin-angiotensin system (RAS) blockers for chronic hypertension in early pregnancy.

Bilal Ahmed1, Duong T Tran2, Helga Zoega3, Sean E Kennedy4, Louisa R Jorm2, Alys Havard2.   

Abstract

OBJECTIVE: Previous research reported greater risk of adverse perinatal outcomes associated with first trimester exposure to angiotensin converting enzyme inhibitors (ACEIs) in comparison to unexposed pregnancies among non-hypertensive women. We examined the relationship between first trimester exposure to ACEIs and angiotensin receptor blockers (ARBs), and maternal and perinatal outcomes, whilst controlling for the underlying hypertension. STUDY
DESIGN: We performed a population-based cohort study among 130,061 pregnancies resulting in birth in NSW, Australia between 2005 and 2012. Birth data were linked to hospital discharge and pharmaceutical dispensing records. After restricting to women with chronic hypertension, 67 and 73 pregnancies exposed to ACEIs and ARBs respectively during the first trimester were compared with 316 pregnancies exposed to methyldopa. STUDY OUTCOMES: Preterm delivery, caesarean section, low birth weight, small for gestational age and Apgar score <7.
RESULTS: Compared to pregnancies exposed to methyldopa, the adjusted odds ratio (aOR) for ACEI exposure was 0.5 (95% CI: 0.2-1.1) for preterm delivery, 1.6 (0.8-3.1) for caesarean section, 0.6 (0.2-1.3) for LBW and 0.8 (0.4-1.9) for SGA. The corresponding aORs and confidence intervals for ARB exposure were 0.7 (0.3-1.5), 1.2 (0.6-2.6), 1.3 (0.7-2.6), and 1.2 (0.6-2.4).
CONCLUSION: No association between early pregnancy exposure to ACEIs and ARBs and perinatal outcomes was observed, however, the possibility of an association cannot be ruled out due to limited power. Nonetheless, this study suggests that the magnitude of risk is smaller than that reported previously.
Copyright © 2018 International Society for the Study of Hypertension in Pregnancy. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30527105     DOI: 10.1016/j.preghy.2018.09.010

Source DB:  PubMed          Journal:  Pregnancy Hypertens        ISSN: 2210-7789            Impact factor:   2.899


  3 in total

1.  The changing face of Australian data reforms: impact on pharmacoepidemiology research.

Authors:  Juliana de Oliveira Costa; Claudia Bruno; Andrea L Schaffer; Smriti Raichand; Emily A Karanges; Sallie-Anne Pearson
Journal:  Int J Popul Data Sci       Date:  2021-04-15

2.  Effect and Role of miR-196b in Ectopic Pregnancy.

Authors:  Shan Deng; Xiaofeng Su; Xiaoling Li; Xiaomiao Shen; Shengru Chen; Xiaoman Lin; Mushi Ye
Journal:  J Healthc Eng       Date:  2022-02-28       Impact factor: 2.682

3.  Adverse pregnancy outcomes associated with first-trimester exposure to angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers: A systematic review and meta-analysis.

Authors:  Nida Buawangpong; Supanimit Teekachunhatean; Nut Koonrungsesomboon
Journal:  Pharmacol Res Perspect       Date:  2020-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.